To determine the usefulness of the rapid parathyroid hormone (PTH) assay during venous localization for primary hyperparathyroidism (1°HPTH).
Objective
To determine the usefulness of the rapid parathyroid hormone (PTH) assay during venous localization for primary hyperparathyroidism (1°HPTH).
Summary Background Data
Remedial exploration for persistent 1°HPTH poses a significant challenge when noninvasive preoperative localization studies are negative. Based on experience with the intraoperative rapid PTH assay, this technique was extrapolated to the interventional radiology suite and generated near real-time data for the interventional radiologist employing on-site hormone analysis, with a 12-minute turnaround time from blood sampling to assay result.
Methods
Between November 1997 and July 2002, 446 patients with 1°H PTH were referred for treatment. Of these, 56 (12.5%) represented remedial patients who had each undergone one or more previous cervical explorations. Noninvasive imaging studies were positive for or suggestive of localized disease in 49/56 (87.5%) of these patients, who therefore proceeded directly to surgical exploration. Seven patients with persistent 1°HPTH and negative noninvasive studies underwent selective venous sampling employing a rapid PTH assay in the interventional suite.
Results
Venous localization demonstrated an apparent PTH gradient in six of the seven patients. In three, a subtle gradient demonstrated in near real-time prompted additional sampling, which confirmed an unequivocal hormone gradient. In an additional case, the absence of a gradient on initial sampling prompted further sampling, which was positive. All of the patients were explored, and in five of the six patients with a positive PTH gradient, a parathyroid adenoma (mean weight 636 Ϯ 196 mg) was resected from a location predicted by venous localization. In the sixth patient with a positive gradient, parathyroid tissue was not identified; however, there was a significant fall in the intraoperative PTH values, and immediate postoperative and follow-up laboratory data at 1 month are indicative of a cure. In the one patient with negative localization, abnormal parathyroid tissue could not be located during surgical exploration.
Conclusions
The rapid PTH assay is a major adjunct for obtaining informative venous localization in patients with persistent 1°HPTH. This information is extremely helpful to the surgeon in this challenging group of patients and resulted in a 100% cure rate when a venous gradient was demonstrated. The authors now employ this technique routinely in remedial patients with negative noninvasive imaging studies.
Surgical treatment of patients with primary hyperparathyroidism (1°HPTH) is associated with cure rates that exceed 95% and complication rates in the 1% to 2% range when the operation is performed by an experienced parathyroid surgeon. Unfortunately, a subset of patients fail initial parathyroid surgery and require remedial exploration, which is associated with increased morbidity, cost, and operative failure. 1 Reexploration is inherently more difficult due to fibrosis and anatomic distortion that makes parathyroid resection challenging and recurrent nerve preservation precarious. 2 It is standard care to perform preoperative parathyroid localization in all patients who require remedial exploration for 1°HPTH. 3 Noninvasive studies, including sestamibi scans, ultrasound, MRI, and CT scans, are commonly employed. When one or more of these studies are informative, the patients proceed to surgical exploration. Unfortunately, a subset of these patients have noninformative studies and are, therefore, referred for selective venous sampling (SVS) and arteriography. 4 In the past, angiographers would obtain multiple venous samples from the cervical and mediastinal regions and send blood samples for delayed PTH analysis. The inherent lag time of 1 to 7 days imposed by this technique occasionally resulted in compromised cases due to insufficient sampling and mislabeling of specimens. Although this technique has been useful, we hypothesized that employment of the rapid PTH assay in the interventional suite might be beneficial and might help guide the interventionalists to an accurate study. In 2000, we reported the initial patient who underwent this procedure. 5 The current cumulative series represents our experience with the first seven cases.
METHODS
All patients referred with a diagnosis of 1°HPTH underwent a detailed history and physical examination as well as confirmatory laboratory testing. Patients with an elevated or inappropriate serum PTH level in conjunction with hypercalcemia were considered for surgical exploration. Patients who had not undergone previous cervical exploration underwent either conventional or minimally invasive parathyroid surgery. 6 Patients with persistent or recurrent 1°HPTH underwent careful review of all operative imaging and pathologic studies, and further noninvasive preoperative imaging studies were performed. If the studies demonstrated parathyroid localization, the patients were explored. When noninvasive studies were inconclusive, these patients underwent SVS employing the rapid on-site PTH assay in the interventional suite. Angiography SVS was originally described by Bilzekian et al. 7 All of our patients had common femoral vein punctures and insertion of a 6 French sheath with a sidearm flush of heparinized saline. Patients received 3,000 units of heparin intravenously after venous access was established.
Analysis of blood from the iliac vein was performed before selective sampling. Sample volumes of 3 to 5 cc 3 were obtained using a 5 French Berenstein catheter (Angio-Dynamics, Queensbury, NY) from the internal jugular vein at the high, middle, and low positions. Thyroidal branches were searched for and selectively sampled with 5 French catheters of various shapes, including Simmons 1, Internal Mammary, and Multipurpose, depending on the angle of the venous branch and the diameter of the jugular vein.
Extensive sampling was performed from the brachioce-phalic, ima, thymic, and vertebral veins bilaterally. When small veins were encountered that could not be selectively catheterized, a microcatheter was advanced coaxially through the 5 French system for selective sampling. Second-and third-order branches of the jugular and vertebral veins can easily be interrogated with this technique. If the thymic veins could not be successfully catheterized, then blood was obtained from along the inferior surface of the left brachiocephalic vein, where these veins invariably drain. A contrast venogram was obtained at each catheter position with digital subtraction angiography to document the patterns of venous drainage. Results were filmed, with the PTH assay results annotated on each image. Additionally, an anatomic map was created to display the location of assay results. Sampling continued until a positive assay was obtained or no additional veins could be catheterized to reveal a significant gradient. If equivocal results were obtained, the assay results were available for review and additional samples were obtained in any area demonstrating a subtle gradient. PTH analysis was performed in the adjoining angiography suite and the results were reviewed with the angiographer in real time.
Arteriography
Arteriography was used selectively to further evaluate the results of venous sampling. Common femoral artery access was obtained. Selective catheterization of the external carotid artery, thyrocervical trunk (to opacify the inferior thyroid artery), or internal mammary artery was performed, depending on the suspected location of the lesion. The angiogram was considered positive when a discrete area of contrast enhancement was demonstrated.
PTH Assay
Blood samples were analyzed in the interventional suite using the Quick-IntraOperative Intact PTH assay (Nichols Institute Diagnostics) as previously reported. 8 In brief, this immunochemiluminometric assay employs two goat polyclonal antibodies against PTH, one coated on a polystyrene bead and another labeled with an acridinium ester. The assay measures intact PTH, and its performance characteristics demonstrate a lag time from EDTA blood sample to hormone value of 12 minutes. The intra-assay imprecision CV is 12% at 28 pg/mL and 11% at 278 pg/mL, with a detection limit of 11 pg/mL at Hopkins. 8 At Yale, the CV is 10.7% at 32 pg/mL and 5.3% at 216 pg/mL, with a lower limit of detection of 6 pg/mL.
Data Analysis
All data were collected prospectively and stored in a computerized database. Data are reported as the group mean Ϯ SEM unless otherwise indicated.
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RESULTS
Between November 1997 and July 2002, 446 patients with a confirmed diagnosis of 1°HPTH were explored by a single endocrine surgeon (R.U.). Within this population, 56 patients (12.5%) presented with persistent (n ϭ 30) or recurrent (n ϭ 13) disease, having undergone one or more previous cervical explorations. In addition, 13 patients had undergone previous thyroidectomy. Noninvasive preoperative imaging studies were performed in all of these patients and were deemed positive or suggestive of localized disease in 49 of the 56 patients (87.5%), who proceeded directly to surgical exploration.
Seven patients, all with persistent 1°HPTH and negative noninvasive studies, elected to undergo SVS employing the rapid PTH assay in the interventional suite. Five (71.4%) were female, with a mean group age of 60 Ϯ 5 years (range 35-72 years). All of these patients had failed previous parathyroid explorations on one to three occasions, and two had also undergone partial thyroidectomy. The patients were all symptomatic, demonstrating fatigue or lethargy (86%), mental status changes (86%), and/or osteoporosis (57%). They presented following their initial exploration with a mean intact serum PTH level of 137 Ϯ 19 pg/mL (range 96 -209 pg/mL; normal range 10 -65 pg/mL) and serum calcium level of 11.3 Ϯ 0.2 mg/dL (range 10.4 -12.0 mg/dL; normal range 8.4 -10.5 mg/dL). Negative noninvasive studies included sestamibi (n ϭ 7), ultrasound (n ϭ 6), CT (n ϭ 2), and MRI scans (n ϭ 5).
Angiography Findings
Venous sampling was positive in six of the seven patients (86%), as demonstrated in Table 1 . Employment of the rapid PTH assay in the interventional suite afforded the angiographers near real-time (12-minute turnaround time per sample) feedback, allowing on-site determination of positive PTH gradients. In three of the seven patients a subtle but nondiagnostic gradient prompted additional sampling, which demonstrated an unequivocal gradient. In a fourth case (patient 6), the absence of a gradient on 19 consecutive samples prompted additional sampling, which resulted in a positive study on samples 20, 21, and 22 ( Fig. 1) .
This patient, a 68-year-old man, had been living in a nursing home because of marked confusion and lethargy associated with a serum calcium level of 15.6 mg/dL and an intact serum PTH level of 400 pg/mL. He was explored at an outside institution employing an intraoperative gamma probe. 9 Despite a bilateral cervical exploration, abnormal parathyroid tissue was not identified. His postoperative hypercalcemia was managed with intravenous pamidronate and he was referred for additional management, at which time he was noted to have a paralyzed left true vocal cord.
The results of his venous localization, demonstrated in Figure 1 , revealed a marked gradient from a posterior branch of the right superior thyroid vein. Surgical exploration was performed using a right lateral approach, and a 740-mg ectopic parathyroid adenoma was resected from the right retroesophageal position.
Arteriography
Arteriography was selectively employed based on the venous gradients. Figure 2A demonstrates the venous PTH levels in patient 4. Selective venography of the left vertebral vein with superimposed PTH values is shown in Figure 2B . Selective arteriography based on this venous gradient demonstrated a tumor blush (arrows in Fig. 2C ). In three of the five cases in which an arteriogram was performed, a tumor blush confirmed the venous localization findings. In case 1, arteriography precisely localized a parathyroid adenoma that had been regionalized by venous sampling (see Table 1 ). All angiography was performed on an outpatient basis, and there were no complications.
Operative Findings
Operative exploration was dictated by the angiography findings and was limited whenever possible. The intraoperative PTH assay was used in all cases and the operation was terminated when an adequate decrement (50% reduction) in PTH levels was demonstrated following parathyroid adenoma resection. 6, 10 The results of the PTH assay for the seven patients are demonstrated in Figure 3A . In six of the seven patients, a significant reduction in the intraoperative PTH levels was noted following parathyroid adenoma resection.
In five of the six patients in whom a positive gradient was identified, a single parathyroid adenoma was identified and resected from the predicted location (see Fig. 3B ). The mean weight of the excised glands was 636 Ϯ 196 mg (range 240 -1,340 mg). In the sixth patient with a positive gradient, no parathyroid tissue was identified despite an extensive bilateral cervical exploration as well as a complete transsternal mediastinal exploration. However, during the case, the intraoperative PTH assay demonstrated a significant reduction from a baseline value of 105 to 23 pg/mL, which was indicative of cure. Although pathologic review of the specimen failed to demonstrate abnormal parathyroid tissue, a sustained cure was achieved. At 1 month follow-up, her serum calcium level was 9.4 mg/dL compared to her preoperative level of 11.7 mg/dL. The one patient who did not have a positive gradient also underwent an extensive remedial exploration; however, abnormal parathyroid tissue was not identified, the intraoperative PTH assay failed to demonstrate a significant reduction, and the patient has persistent disease. There were no perioperative complications in this cohort of seven patients, and long-term hormone results demonstrated durable cures in six of the seven patients, with a mean serum calcium level of 9.0 Ϯ 0.2 mg/dL at 14 months.
DISCUSSION
Surgery for 1°HPTH remains the curative treatment of choice for the majority of patients. Recent improvements in imaging and refinement of surgical techniques have led to the adoption of an array of minimally invasive procedures that are being employed in select centers. 6,9 -11 Despite these improvements, a subset of patients will continue to fail initial exploration or will develop recurrent disease.
Noninvasive imaging studies are always employed before remedial exploration for 1°HPTH. Unfortunately, a subset of patients who undergo noninvasive studies will not demonstrate adequate localization. In these select cases, invasive imaging by an experienced angiographer is indicated. Employment of the rapid PTH assay in the interventional suite is analogous to using this assay in the operating room.
There are subtle findings on venous localization studies that must be appreciated. A PTH gradient in a branch of the superior thyroid vein will occur in the setting of retroesophageal and descended upper glands, which not uncommonly are found in the lower cervical region. Furthermore, previous surgery often makes the cervical venous anatomy challenging to transverse with a catheter to obtain sufficient samples.
Availability of near real-time PTH values 12 minutes after blood sampling yields the angiographer information that allows him or her to 1) terminate the study with the knowledge that a diagnostic study has been achieved, 2) obtain additional samples to verify a subtle but nondiagnostic study, 3) persist and obtain additional samples, knowing that not even a subtle gradient has been demonstrated, and/or 4) guide selective arteriography in the setting of a positive venous gradient. Based on our experience with on-site PTH analysis, we now employ this technique for all cases of parathyroid venous localization. The concept of on-site hormone analysis may have broad ramifications for other assays and diseases. Udelsman for a very thorough and thoughtful study and analysis. As you have heard today, the surgical treatment of hyperparathyroidism has really dramatically changed over the past several years, with the focus on more minimally invasive techniques. In the current era, most patients with positive preoperative imaging tests are now treated with a directed parathyroidectomy or a unilateral exploration. In many cases this can be performed under regional or local anesthesia and in the outpatient setting.
In its various applications, the shift in the paradigm in treating patients with parathyroid disease these days is really based on better noninvasive imaging tests, the sestamibi scan, in some people's hands the application of a hand-held gamma counter intraoperatively to assist in localizing the tumors, and then finally, the use of intraoperative rapid parathyroid hormone assays. And that last advance certainly in our experience has been the most important one in addressing the most common pitfalls of a unilateral approach, specifically that being the possibility of multiglandular disease. It provides a way to actually have a biochemical application of cure.
Dr. Udelsman has an extensive personal experience in the treatment of parathyroid disease and has reported his excellent results. In this current report he really focuses on a very select subgroup of patients, those with persistent or recurrent hyperparathyroidism in which noninvasive imaging tests are not informative or a negative. And you will note that all of these, a very small number of patients, only seven, understandably, also all of them had negative nuclear medicine sestamibi scans, and, as I understand it, six of them had negative ultrasounds.
It is well recognized that these patients have a very challenging surgical management associated with increased morbidity, costs, and the possibility of failure. So this study really expands the application of rapid parathyroid hormonal assay to the venous sampling in the angiography suite.
The authors conclude that the application of this rapid test in near real time, the ability to receive results quickly, somehow influences the progress or directs the progress of the study and presumably increases its accuracy. I have the following questions for Dr. Udelsman.
In patients with persistent disease that have negative noninvasive imaging tests, how do you choose between selective venous sampling alone or arteriography? You alluded to the fact that arteriography is performed selectively based on the results of the venous sampling. But some would argue that arteriography by itself has as good a detection rate of these tumors as selective venous sampling, which can be cumbersome, it can be complex. I also would like to ask you if you think that patients who have had extensive prior neck explorations somehow compromises the ability to obtain meaningful results with selective venous sampling.
Finally, the central theme on which the conclusions are based is the notion that the ability to receive the results immediately directs the progress of the study and improves the detection rates, if I understand your conclusions. In the manuscript it indicates that three of the patients, three of the seven, had a subtle gradient that was confirmed with additional sampling and that one patient with a negative test, you persisted until a gradient was found. However, it appears from your table that one of the tumors was detected or accurately localized by arteriography alone, that in fact the gradient was not indicative of the anatomical position of the tumor.
So do you believe that the application of the rapid assay significantly increased the utility of the study? In other words, would these patients have not been localized if the parathyroid hormone levels had been delayed in coming back? Or do you feel that it just facilitates the use of the technique?
Finally, I can't help but just ask you to comment briefly on the number of samples that some of these patients took and the potential complexity and cost of the study. Certainly we all recognize that these are very difficult patients to take care of if they failed one or more explorations previously and had negative studies. But you had anywhere from 14 to 41 samples, all of which have to be assayed with a rapid PTH determination.
I enjoyed very much the manuscript. I think it is a good contribution to the literature. And I greatly appreciate the opportunity to review it in advance.
DR. RICHARD E. GOLDSTEIN (Louisville, KY): In the past, ordering a venous sampling study for a patient with primary hyperparathyroidism was largely a procedure of last resort. It was a final and often last-ditch attempt to identify at best a particular quadrant of the neck, and often only a single side of the neck, where one hoped to find the parathyroid adenoma that had been missed by at least one and often more than one operative procedure.
In this setting, one was almost always dealing with an individual who was very symptomatic and debilitated by this disease process. The protocol outlined in Dr. Udelsman's manuscript merges logic and the latest technology. Previously, an intense venous sampling study would consist of drawing 12 to 15 samples from different regions of the neck for serum PTH. The patient would go home. One week later one would get the values back. Not infrequently, a step-up would be seen in only one or at most two samples; one would be left wondering if this was in fact real, or lab error; much less trying to figure out exactly where the adenoma was.
The data that has just been presented to me reflects a major advancement in the interrogation of patients with complicated parathyroid disease. I would now like to ask Dr. Udelsman a few questions.
In my experience, a step-up in the parathyroid hormone level high in the neck is in fact usually real and reflects a missed superior adenoma. However, a step-up in the parathyroid hormone level low can reflect an inferior or mediastinal adenoma, or, as you pointed out, can reflect also a superior gland with altered drainage, presumably due to tying off the vessels in the previous procedures. It looked from the data certainly as if one and possibly a second patient had such altered drainage. Could you comment on this, not just from the series but from other patients who you have had experience with, and comment on your operative technique? For these patients do you start operating low, identify the patient's recurrent nerve, and then work upward? What is the best way to actually approach these patients?
As Dr. Lairmore indicated, clearly this is a very time-consuming procedure, and four of these seven patients had 29 or more samples drawn to be measured. Could you comment on the time needed for this study and speculate on the cost, although I recognize that these patients needed this procedure? And as far as coordinating this procedure, do you have the samples batched at all? Or do you simply have them processed by the lab as the samples are drawn?
My third topic deals with the fact that several of your patients did not have either CT scans or MRIs of the neck. Previous data indicated that for parents who need reoperative surgery, one should order both of those studies, as they can be complementary. Usually we certainly try to exhaust the relatively noninvasive studies before moving on to the sampling. But now that we have the ability the measure the parathyroid hormone level at the time of venous sampling, could you comment on where you think venous sampling fits into the work-up of these patients?
DR. ROBERT UDELSMAN (New Haven, Connecticut): I would like to thank the discussants for their thoughtful questions.
Dr. Lairmore asked several questions. The first was, what was our protocol for selective venous sampling? And the answer is, it has really evolved over time, going way back to my days at the NIH with John Doppman and subsequently at Hopkins and now at Yale. But the bottom line is that we only use venous sampling in remedial exploration patients with negative noninvasive imaging studies. This is a retrospective study. Five of the patients had arteriography. When it was used, it was useful. Obviously you need arterial catheterization in addition to venous catheterization, so it does complicate the study. At least in one patient I showed you today it was very useful because of the altered venous anatomy. The altered venous anatomy point was made by several discussants in that many surgeons, when they explore these patients unsuccessfully, ligate the middle thyroid veins, the inferior thyroid veins, and the superior thyroid veins. Those are the very veins we need for sampling in this very complicated group of patients. These patients can develop contralateral cross-over communications, as described by Doppman and others. They can thus produce confusing studies. The answer is, prior neck exploration severely complicates and compromises not only remedial surgery but also venous sampling.
The question Dr. Lairmore asked, which was very provocative, is, does the assay really make a difference to the angiographers? It does add cost. Does it really help? And the answer is, I think it does. I remember the old days when we would get 20 or 30 samples and get the results back a week later and maybe have one positive sample. And then we would question, could there have been a sampling error due to the labeling process? So when you went to surgery and you couldn't find the parathyroid adenoma, or you ended up on the other side, you would say, 'What in the world was this information worth?' So the answer is, I think it makes a difference, but I can't prove it with the data shown you today.
What about cost? Well, this is not inexpensive. Then again, failed parathyroid surgery, as shown by Jeff Norton and his colleagues at Barnes and now in San Francisco, is extraordinarily expensive. These are complicated patients. We never do these studies for routine patients. These are only the worst of the worst, those who have failed previous surgery, those who have had negative studies, and those who require remedial exploration. It is justified in this highly select group of patients.
Was it really costly? You need a technician in the angiography suite. And we analyze the sample immediately. It is on time and realtime, which means 12 minutes from blood to number. What does it really cost for the assay? We buy them by the kit. We do so many parathyroid surgeries now we have the costs way down.
Dr. Goldstein asked several questions. One question I immediately respond to is the question of lab error and mislabeling. It can be a serious problem. I believe that is minimized by realtime information. He commented about the superior glands. When you get a very high gradient in the neck, I agree, that is almost always a non-descended gland. Those are relatively straightforward. When they are lower glands it is easy to be confused. A lower gradient can mean a mediastinal gland, because the blood supply is usually from above and sometimes it is difficult to differentiate anterior versus posterior mediastinum.
Operative technique. The goal of surgery in remedial patients like this is to do as little as possible and cure the patient. It is not a standard bilateral exploration. In fact, what you hate to do is to have to go on both sides, especially in the setting of a recurrent nerve injury, before you even get there. So if you know where that adenoma is, it makes that operation straightforward most of the time.
Where do we start? We go for the money. It is real simple. In a remedial case if we have a posterior retroesophageal gland, that is easy. We simply use a lateral approach through the carotid sheath, get to the nerve early and find a parathyroid gland. It can be a 20-minute operation. And the intraoperative parathyroid hormone assay is very useful.
The question about does every patient for remedial surgery require the whole gamut of scans reported by the NIH group -everybody got everything. I frankly have been very disappointed with CT and MRI scans, and perhaps that is reflected in the scans that I get. I have no objection to them, but they have not been very useful in our hands in the remedial patients.
Finally, the issue comes back again to cost effectiveness. I would argue the single most cost effective method is to have an initial successful operation and the best way to get that is to have the patient explored by an experienced parathyroid surgeon.
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